These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 25600097)

  • 1. Prostate cancer in 2014: The year chemotherapy finally gets some respect!
    Saad F
    Nat Rev Urol; 2015 Feb; 12(2):71-2. PubMed ID: 25600097
    [No Abstract]   [Full Text] [Related]  

  • 2. Long-term Efficacy and Safety Results: Can Enzalutamide Challenge the Dogma of Androgen Deprivation Therapy in Hormone-naïve Prostate Cancer?
    Albiges L; Loriot Y; Massard C; Fizazi K
    Eur Urol; 2015 Nov; 68(5):802-4. PubMed ID: 25922192
    [No Abstract]   [Full Text] [Related]  

  • 3. Metastatic Castration-resistant Prostate Cancer: Piling Up the Benefits of Chemotherapy.
    Tombal B
    Eur Urol; 2015 Aug; 68(2):236-7. PubMed ID: 24908474
    [No Abstract]   [Full Text] [Related]  

  • 4. Towards random sequencing or precision medicine in castration-resistant prostate cancer?
    Loriot Y; Fizazi K
    Eur Urol; 2014 Jan; 65(1):37-8. PubMed ID: 24075577
    [No Abstract]   [Full Text] [Related]  

  • 5. Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.
    Crawford ED; Higano CS; Shore ND; Hussain M; Petrylak DP
    J Urol; 2015 Dec; 194(6):1537-47. PubMed ID: 26196735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Parotid gland metastasis from prostate cancer: is docetaxel still the best treatment option?
    Hélissey C; Rouanne M; Arnaud FX; Le Moulec S
    Anticancer Drugs; 2015 Mar; 26(3):367-70. PubMed ID: 25486600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Advances in the treatment of castration-resistant prostate cancer: emphasis in new hormonal therapies].
    Berlin A; Fernández MI
    Rev Med Chil; 2015 Feb; 143(2):223-36. PubMed ID: 25860365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First-line management of metastatic castrate-resistant prostate cancer patients: Audit of real-life practices.
    Turpin A; Pasquier D; Massard C; Berdah JF; Culine S; Penel N
    Bull Cancer; 2017 Jun; 104(6):552-558. PubMed ID: 28390646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Androgen deprivation therapy in castrate-resistant prostate cancer: how important is GnRH agonist backbone therapy?
    Merseburger AS; Hammerer P; Rozet F; Roumeguère T; Caffo O; da Silva FC; Alcaraz A
    World J Urol; 2015 Aug; 33(8):1079-85. PubMed ID: 25261259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Third-line Enzalutamide Following Docetaxel and Abiraterone in Metastatic Castrate-resistant Prostate Cancer.
    Davies RS; Smith C; Lester JF
    Anticancer Res; 2016 Apr; 36(4):1799-803. PubMed ID: 27069162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [2017 ASCO: Complete androgen blockade strikes back].
    Penel N
    Bull Cancer; 2017; 104(7-8):599-601. PubMed ID: 28688745
    [No Abstract]   [Full Text] [Related]  

  • 12. Skeletal metastases and impact of anticancer and bone-targeted agents in patients with castration-resistant prostate cancer.
    Vignani F; Bertaglia V; Buttigliero C; Tucci M; Scagliotti GV; Di Maio M
    Cancer Treat Rev; 2016 Mar; 44():61-73. PubMed ID: 26907461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [How to manage patients with CRPC?].
    Beuzeboc P; Massard C
    Bull Cancer; 2015 Jun; 102(6):509-15. PubMed ID: 26028494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment of metastatic castration-resistant prostate cancer].
    Caffo O
    Recenti Prog Med; 2015 Jan; 106(1):35-9. PubMed ID: 25621779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of the introduction of novel hormonal agents on metastatic castration-resistant prostate cancer treatment choice.
    Lahcene H; Aprikian AG; Vanhuyse M; Hu J; Bladou F; Cury F; Kassouf W; Perreault S; Dragomir A
    J Oncol Pharm Pract; 2020 Mar; 26(2):293-305. PubMed ID: 30997868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate cancer: AR aberrations and resistance to abiraterone or enzalutamide.
    Attard G; Antonarakis ES
    Nat Rev Urol; 2016 Dec; 13(12):697-698. PubMed ID: 27804988
    [No Abstract]   [Full Text] [Related]  

  • 17. Therapies for castration-resistant prostate cancer in a new era: The indication of vintage hormonal therapy, chemotherapy and the new medicines.
    Mizokami A; Kadono Y; Kitagawa Y; Izumi K; Konaka H
    Int J Urol; 2017 Aug; 24(8):566-572. PubMed ID: 28577511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [DNA damage repair: An emerging strategy in metastatic prostate cancer].
    Loriot Y; Meynard G; Klajer E; Bolognini C; Gassian N; Thiery-Vuillemin A
    Bull Cancer; 2018 Oct; 105(10):944-954. PubMed ID: 30278883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015.
    Gillessen S; Omlin A; Attard G; de Bono JS; Efstathiou E; Fizazi K; Halabi S; Nelson PS; Sartor O; Smith MR; Soule HR; Akaza H; Beer TM; Beltran H; Chinnaiyan AM; Daugaard G; Davis ID; De Santis M; Drake CG; Eeles RA; Fanti S; Gleave ME; Heidenreich A; Hussain M; James ND; Lecouvet FE; Logothetis CJ; Mastris K; Nilsson S; Oh WK; Olmos D; Padhani AR; Parker C; Rubin MA; Schalken JA; Scher HI; Sella A; Shore ND; Small EJ; Sternberg CN; Suzuki H; Sweeney CJ; Tannock IF; Tombal B
    Ann Oncol; 2015 Aug; 26(8):1589-604. PubMed ID: 26041764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate cancer: What is the optimal treatment sequence for mCRPC?
    Sartor O
    Nat Rev Urol; 2016 Oct; 13(11):639-640. PubMed ID: 27797362
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.